These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9540748)

  • 1. An alternative approach to the treatment of oral leukoplakia.
    Page DG; Grisius TM; Clougherty M; Page D
    Va Dent J; 1995; 72(2):10-2. PubMed ID: 9540748
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthetic vitamins used to reverse oral leukoplakia.
    Oncology (Williston Park); 1988 Feb; 2(2):31. PubMed ID: 3275152
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the clinical and histological effectiveness of isotretinoin in the therapy of oral leukoplakia: ten years of experience: is management still up to date and effective?
    Scardina GA; Carini F; Maresi E; Valenza V; Messina P
    Methods Find Exp Clin Pharmacol; 2006 Mar; 28(2):115-9. PubMed ID: 16636722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of apoptosis and bcl-2 protein in topical treatment of oral leukoplakia with isotretinoin.
    Tetè S; Pappalardo S; Rubini C; Salini L; Falco A; Perfetti EG
    Minerva Stomatol; 1999 Sep; 48(9):411-8. PubMed ID: 10638174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of 13-cis-retinoic acid in the treatment of oral leukoplakia: short-term observations.
    Kaugars G; Silverman S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1995 Mar; 79(3):264-5. PubMed ID: 7620998
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoprevention of oral cancer in leukoplakia patients: A systematic review and meta-analysis.
    Xie A; Liu J
    J Pak Med Assoc; 2017 Sep; 67(9):1415-1419. PubMed ID: 28924285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention as a form of cancer control.
    Toth BB; Martin JW; Lippman SM; Hong WK
    J Am Dent Assoc; 1993 Jul; 124(7):243-6. PubMed ID: 8335795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment re: continuous rather than intermittent administration of fenretinide in leukoplakia.
    Formelli F; Cavadini E; Appierto V; Tiberio P; Grigolato R; Chiesa F; Tradati N; Persiani S
    Cancer Prev Res (Phila); 2009 Mar; 2(3):281; author reply 281. PubMed ID: 19258538
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral leukoplakia: open trial of topical therapy with calcipotriol compared with tretinoin.
    Femiano F; Gombos F; Scully C; Battista C; Belnome G; Esposito V
    Int J Oral Maxillofac Surg; 2001 Oct; 30(5):402-6. PubMed ID: 11720042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting cancer development in oral leukoplakia: ten years of translational research.
    Lee JJ; Hong WK; Hittelman WN; Mao L; Lotan R; Shin DM; Benner SE; Xu XC; Lee JS; Papadimitrakopoulou VM; Geyer C; Perez C; Martin JW; El-Naggar AK; Lippman SM
    Clin Cancer Res; 2000 May; 6(5):1702-10. PubMed ID: 10815888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of oral verrucous carcinoma with carbon dioxide laser.
    Azevedo LH; Galletta VC; de Paula Eduardo C; de Sousa SO; Migliari DA
    J Oral Maxillofac Surg; 2007 Nov; 65(11):2361-6. PubMed ID: 17954341
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral leukoplakia in a diabetic patient treated with tretinoin.
    Starzyńska A; Pawłowska A; Niekra M; Oleszkiewicz I; Szmuda T; Chomik P
    Pol Arch Med Wewn; 2013; 123(7-8):419-20. PubMed ID: 23974292
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of oral lycopene in the treatment of oral leukoplakia.
    Singh M; Krishanappa R; Bagewadi A; Keluskar V
    Oral Oncol; 2004 Jul; 40(6):591-6. PubMed ID: 15063387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of oral leukoplakia using drug iontophoresis].
    Peng SY; Xu LM
    Actual Odontostomatol (Paris); 1987 Jun; 41(158):239-44. PubMed ID: 3481947
    [No Abstract]   [Full Text] [Related]  

  • 15. Fenretinide activity in retinoid-resistant oral leukoplakia.
    Lippman SM; Lee JJ; Martin JW; El-Naggar AK; Xu X; Shin DM; Thomas M; Mao L; Fritsche HA; Zhou X; Papadimitrakopoulou V; Khuri FR; Tran H; Clayman GL; Hittelman WN; Hong WK; Lotan R
    Clin Cancer Res; 2006 May; 12(10):3109-14. PubMed ID: 16707609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical retinaldehyde treatment in oral lichen planus and leukoplakia.
    Boisnic S; Licu D; Ben Slama L; Branchet-Gumila MC; Szpirglas H; Dupuy P
    Int J Tissue React; 2002; 24(4):123-30. PubMed ID: 12779246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical experiences with vitamin A acid derivatives in therapy of leukoplakia of the mouth mucosa].
    Koch H; Schettler D
    Dtsch Zahnarztl Z; 1973 May; 28(5):623-7. PubMed ID: 4513569
    [No Abstract]   [Full Text] [Related]  

  • 18. [Oral leukoplasia].
    Tercedor J; Ródenas JM; López Hernández B; Herranz MT
    Med Clin (Barc); 1997 Sep; 109(9):358-9. PubMed ID: 9379774
    [No Abstract]   [Full Text] [Related]  

  • 19. A review of the use of antioxidant supplements in the treatment of human oral leukoplakia.
    Kaugars GE; Silverman S; Lovas JG; Brandt RB; Thompson JS; Singh VN
    J Cell Biochem Suppl; 1993; 17F():292-8. PubMed ID: 8412207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy.
    Chen HM; Yu CH; Tu PC; Yeh CY; Tsai T; Chiang CP
    Lasers Surg Med; 2005 Aug; 37(2):114-22. PubMed ID: 16037967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.